Compound 23

(E)-2-chloro-6-styrylpyrimidine

From: Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer

View in PubChem | 1H NMR | 13C NMR | MDL Molfile | ChemDraw

Synthetic procedure: See article for the definitive version of this procedure and for full experimental details.

Trans-2-phenylvinylboronic acid (0.5 g, 1 eq, 3.6 mmol) was dissolved in 20 mL THF. The catalyst, PdCl2(PPh3)2 (76 mg, 0.03 eq, 0.11 mmol) was added followed by potassium phosphate tribasic (1.5 g, 2 eq, 7.2 mmol). The 2,4-dichloropyrimidine (0.5 g, 1 eq, 3.6 mmol) was dissolved in 4 mL THF and then added to the stirred solution via syringe. Water (3 mL) was added. The flask was equipped with a condenser and brought to a reflux for 24 hours. The reaction was quenched with 20 mL water. The organic products were extracted with 3x25 mL Et2O. They were combined and washed with brine (30 mL), dried over MgSO4 and concentrated under reduced pressure. The product was purified using 10% ethyl acetate in hexanes to yield pure 0.4680 g (64% yield) of off-white solid 23: 1H NMR (500 MHz, CDCl3) δ 8.62 (d, J = 5.1 Hz, 1H), 8.02 (d, J = 16.0 Hz, 1H), 7.74 – 7.64 (m, 2H), 7.53 – 7.45 (m, 2H), 7.31 (d, J = 5.1 Hz, 1H), 7.10 (d, J = 16.0 Hz, 1H). 13C NMR (125 MHz, CDCl3) δ 165.5, 161.5, 159.6, 139.3, 135.0, 129.9, 128.9, 127.9, 126.1, 124.0, 122.7, 116.8. HRMS (ESI+) m/z calcd for C12H10N2Cl+ 217.0533, found 217.0532.